FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

OMB APPROVAL							
OMB Number:	3235-0104						
Estimated average burden							
hours per response	: 0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Add <u>Dunoyer M</u>		2. Date of Event Requiring Statement (Month/Day/Year) 01/01/2020 3. Issuer Name and Ticker or Trading Symbol Orchard Therapeutics plc [ORTX]										
(Last) C/O ORCHAI	(First) RD THERAPE	(Middle) UTICS PLC				ionship of Reporting Perso all applicable) Director	erson(s) to Issuer		5. If Amendment, Date of Original Filed (Month/Day/Year)			
108 CANNON	N STREET					Officer (give title below)	Other (spe below)	cify		lividual or Joint cable Line)	/Group Filing (Check	
(Street) LONDON	X0	EC4N 6EU							X		y One Reporting Person y More than One erson	
(City)	(State)	(Zip)										
Table I - Non-Derivative Securities Beneficially Owned												
1. Title of Security (Instr. 4)					2. Amount of Securities Beneficially Owned (Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Ordinary Shares ⁽¹⁾						37,179	D					
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)												
1. Title of Derivative Security (Instr. 4)		str. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Inst			4. Conver	ersion (ercise F	5. Ownership Form: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
			Date Exercisable	Expiration Date	n Title		Amount or Number of Shares	Price of Derivat Securit	tive	or Indirect (I) (Instr. 5)		
Stock Option (Right to Buy)		(2)	06/11/2028	3	Ordinary Shares	80,030	0.00	01	D		
Stock Option (Right to Buy)		(3)	06/25/2029	9	Ordinary Shares	35,000	13.	2	D		

Explanation of Responses:

- 1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- 2. 26,410 shares subject to this option vested on June 6, 2019 and the remaining shares vest in equal monthly installments over the two years thereafter.
- 3. All of the shares subject to this option vest upon the earlier to occur of June 26, 2020 or the date of the 2020 Annual General Meeting of the Company.

Remarks:

Exhibit 24 - Power of Attorney

/s/ Marc Dunoyer

01/02/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

The undersigned hereby constitutes and appoints each of John Ilett, Mark Rothera, and Frank

Thomas, signing singly, and with full power of substitution, the undersigned's true and

lawful attorney-in-fact to:

- execute for and on behalf of the undersigned, in the undersigned's (1) capacity
- as officer and/or director of Orchard Therapeutics plc (the "Company"), from time to time
- the following U.S. Securities and Exchange Commission ("SEC") forms: (i) Form ID, including
- any attached documents (such as Update Passphrase Authentication), to effect the assignment
- of codes to the undersigned to be used in the transmission of information to the SEC using
- the EDGAR System; (ii) Form 3, Initial Statement of Beneficial Ownership of Securities,
- including any attached documents; (iii) Form 4, Statement of Changes in Beneficial Ownership
- of Securities, including any attached documents; (iv) Form 5, Annual Statement of Beneficial
- Ownership of Securities in accordance with Section 16(a) of the Securities Exchange Act of
- 1934, as amended, and the rules thereunder, including any attached documents; (v) Schedule
- 13D and (vi) amendments of each thereof, in accordance with the Securities Exchange Act of
- 1934, as amended, and the rules thereunder, including any attached documents;
- do and perform any and all acts for and on behalf of the undersigned (2) which
- may be necessary or desirable to complete and execute any such Form 3, 4 or 5, Schedule 13D
- or any amendment(s) thereto, and timely file such form(s) with the SEC and any securities
- exchange, national association or similar authority; and
- take any other action of any type whatsoever in connection with the (3) foregoing
- which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of,
- or legally required by, the undersigned, it being understood that the documents executed by
- such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall
- be in such form and shall contain such terms and conditions as such attorney-in-fact may approve
- in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact, acting singly, full power

and authority to do and perform any and every act and thing whatsoever requisite, necessary or

proper to be done in the exercise of any of the rights and powers herein granted, as fully to all

intents and purposes as the undersigned might or could do if personally present, with full power

of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or

such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue

of this power of attorney and the rights and powers herein granted. The undersigned acknowledges

that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned,

are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply

with Section 16 or Regulation 13D-G of the Securities Exchange Act of 1934, as amended. The

undersigned hereby agrees to indemnify the attorneys-in-fact and the Company from and against

any demand, damage, loss, cost or expense arising from any false or misleading information provided

by the undersigned to the attorneys-in-fact.

This Power of Attorney shall be governed by, and construed in accordance with, the laws of

the state of Delaware. This Power of Attorney shall remain in full force and

undersigned is no longer required to file such forms with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. This Power of Attorney supersedes any prior power of attorney in connection with the undersigned's capacity as an officer and/or director of the Company. This Power of Attorney shall expire as to any individual attorney-in-fact if such attorney-in-fact ceases to be an officer of, or legal counsel to, the

effect until the

Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of January 2, 2020.

/s/ Marc Dunoyer
----Marc Dunoyer